1. Home
  2. IONS vs AIZ Comparison

IONS vs AIZ Comparison

Compare IONS & AIZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

IONS

Ionis Pharmaceuticals Inc.

SELL

Current Price

$42.38

Market Cap

12.1B

Sector

Health Care

ML Signal

SELL

Logo Assurant Inc.

AIZ

Assurant Inc.

SELL

Current Price

$270.99

Market Cap

13.9B

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
IONS
AIZ
Founded
1989
1892
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Property-Casualty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
12.1B
13.9B
IPO Year
1996
2003

Fundamental Metrics

Financial Performance
Metric
IONS
AIZ
Price
$42.38
$270.99
Analyst Decision
Buy
Strong Buy
Analyst Count
24
7
Target Price
$83.64
★ $326.67
AVG Volume (30 Days)
★ 3.9M
350.3K
Earning Date
10-28-2026
11-03-2026
Dividend Yield
N/A
★ 1.31%
EPS Growth
★ 21.71
17.08
EPS
N/A
★ 11.34
Revenue
N/A
★ $12,814,300,000.00
Revenue This Year
N/A
$8.31
Revenue Next Year
$48.21
$5.33
P/E Ratio
★ N/A
$23.69
Revenue Growth
N/A
★ 7.89
52 Week Low
$42.63
$206.03
52 Week High
$86.74
$303.94

Technical Indicators

Market Signals
Indicator
IONS
AIZ
Relative Strength Index (RSI) 33.59 48.30
Support Level N/A $260.64
Resistance Level $46.95 $287.38
Average True Range (ATR) 1.55 5.21
MACD 0.38 0.71
Stochastic Oscillator 7.89 72.56

Price Performance

Historical Comparison
IONS
AIZ

About IONS Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).

About AIZ Assurant Inc.

Assurant Inc is a protection company that partners with the brands to safeguard and service connected devices, homes and automobiles. It operate in North America, Latin America, Europe and Asia Pacific through two operating segments: Global Lifestyle and Global Housing. Global Lifestyle: includes mobile device solutions, consumer electronics and appliances services, and financial services and other insurance products. Global Housing: includes lender-placed homeowners, manufactured housing and flood insurance, as well as voluntary manufactured housing, condominium and homeowners insurance. In addition, the Company reports the Corporate and Other segment, which includes corporate employee-related expenses, activities of the holding company and investments in the home warranty business.

Share on Social Networks: